Copy to clipboard 
Stryker reported 1Q25 orthopedic sales of $2.76 billion, up 9.4% compared to the first quarter of 2024.
The company attributed its multi-year run of high-single-digit to double-digit growth to its consistent execution and adoption of robotic procedures. Appetite for capital and procedure volume are expected to remain healthy through 2025.
Stryker said the first quarter of 2025 was its largest ever for Mako installations. The company’s spine robot is set for full commercial launch in the second half of this year, with Mako Shoulder hitting the market in the first quarter of 2026.
International markets remain a key growth driver for Stryker, with Japan, South Korea, Canada and Europe contributing the company’s impressive orthopedic growth.
The company expects 2025 total organic revenue growth between 8.5% and 9.5%, with an estimated $200 million impact from tariffs.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $1,319.1 | $1,199.7 | $119.4 | 10% |
| Knees | $639.5 | $588.2 | $51.3 | 8.7% |
| Hips | $443.4 | $393.6 | $49.9 | 12.7% |
| Extremities | $236.2 | $217.9 | $18.3 | 8.4% |
| Spine | $166.0 | $170.9 | ($4.9) | (2.9%) |
| Trauma | $708.6 | $612.3 | $96.3 | 15.7% |
| Sports Medicine | $215.6 | $198.1 | $17.4 | 8.8% |
| Orthobiologics | $76.1 | $75.5 | $0.6 | 0.8% |
| Enabling Technology | $105.9 | $103.9 | $2.0 | 1.9% |
| Other | $176.5 | $169.8 | $6.7 | 3.9% |
| Total | $2,767.7 | $2,530.2 | $237.5 | 9.4% |
Orthopedic Sales by Geography
| Region | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,985.1 | $1,811.1 | $173.9 | 9.6% |
| OUS | $782.7 | $719.1 | $63.6 | 8.8% |
| EMEA | $384.7 | $347.9 | $36.8 | 10.6% |
| Asia Pacific | $276.8 | $253.0 | $23.8 | 9.4% |
| Rest of World | $121.2 | $118.2 | $3.0 | 2.6% |
| Total | $2,767.7 | $2,530.2 | $237.5 | 9.4% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $5,866.0 | |
| Cost of Sales | $2,122.0 | 36.2% |
| Selling and Admin | $2,300.0 | 39.2% |
| R & D | $405.0 | 6.9% |
| R & D | $405.0 | 6.9% |
| Other | $385.0 | 6.6% |
| Net Earnings | $654.0 | 11.1% |
Stryker reported 1Q25 orthopedic sales of $2.76 billion, up 9.4% compared to the first quarter of 2024.
The company attributed its multi-year run of high-single-digit to double-digit growth to its consistent execution and adoption of robotic procedures. Appetite for capital and procedure volume are expected to remain healthy through...
Stryker reported 1Q25 orthopedic sales of $2.76 billion, up 9.4% compared to the first quarter of 2024.
The company attributed its multi-year run of high-single-digit to double-digit growth to its consistent execution and adoption of robotic procedures. Appetite for capital and procedure volume are expected to remain healthy through 2025.
Stryker said the first quarter of 2025 was its largest ever for Mako installations. The company’s spine robot is set for full commercial launch in the second half of this year, with Mako Shoulder hitting the market in the first quarter of 2026.
International markets remain a key growth driver for Stryker, with Japan, South Korea, Canada and Europe contributing the company’s impressive orthopedic growth.
The company expects 2025 total organic revenue growth between 8.5% and 9.5%, with an estimated $200 million impact from tariffs.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $1,319.1 | $1,199.7 | $119.4 | 10% |
| Knees | $639.5 | $588.2 | $51.3 | 8.7% |
| Hips | $443.4 | $393.6 | $49.9 | 12.7% |
| Extremities | $236.2 | $217.9 | $18.3 | 8.4% |
| Spine | $166.0 | $170.9 | ($4.9) | (2.9%) |
| Trauma | $708.6 | $612.3 | $96.3 | 15.7% |
| Sports Medicine | $215.6 | $198.1 | $17.4 | 8.8% |
| Orthobiologics | $76.1 | $75.5 | $0.6 | 0.8% |
| Enabling Technology | $105.9 | $103.9 | $2.0 | 1.9% |
| Other | $176.5 | $169.8 | $6.7 | 3.9% |
| Total | $2,767.7 | $2,530.2 | $237.5 | 9.4% |
Orthopedic Sales by Geography
| Region | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,985.1 | $1,811.1 | $173.9 | 9.6% |
| OUS | $782.7 | $719.1 | $63.6 | 8.8% |
| EMEA | $384.7 | $347.9 | $36.8 | 10.6% |
| Asia Pacific | $276.8 | $253.0 | $23.8 | 9.4% |
| Rest of World | $121.2 | $118.2 | $3.0 | 2.6% |
| Total | $2,767.7 | $2,530.2 | $237.5 | 9.4% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $5,866.0 | |
| Cost of Sales | $2,122.0 | 36.2% |
| Selling and Admin | $2,300.0 | 39.2% |
| R & D | $405.0 | 6.9% |
| R & D | $405.0 | 6.9% |
| Other | $385.0 | 6.6% |
| Net Earnings | $654.0 | 11.1% |
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
